We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
- Authors
Jifang Gong; Tianshu Liu; Qingxia Fan; Li Bai; Feng Bi; Shukui Qin; Jinwan Wang; Nong Xu; Ying Cheng; Yuxian Bai; Wei Liu; Liwei Wang; Lin Shen; Gong, Jifang; Liu, Tianshu; Fan, Qingxia; Bai, Li; Bi, Feng; Qin, Shukui; Wang, Jinwan
- Abstract
<bold>Background: </bold>The ToGA study showed that trastuzumab plus chemotherapy prolonged median survival in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. Among chemotherapy options, oxaliplatin might be as effective as cisplatin but has shown to be more tolerable. To further improve treatment options for patients with advanced gastric cancer, we initiated a study to evaluate the efficacy and safety of trastuzumab plus oxaliplatin/capecitabine in patients with HER2-positive advanced gastric cancer.<bold>Methods: </bold>CGOG1001 was an open-label, multicenter, prospective phase II study. Patients with chemotherapy-naive HER2-positive advanced gastric cancer were eligible. Trastuzumab was administered at a loading dose of 8 mg/kg followed by 6 mg/kg infusion every 3 weeks (q3w). Oxaliplatin was administrated as a 130 mg/m(2) infusion, q3w, for up to 6 cycles. Capecitabine 1000 mg/m(2) was given orally twice daily on days 1-14 followed by a 7-day rest interval. Trastuzumab and capecitabine were continued until disease progression or intolerable toxicity. The primary endpoint was objective response rate. Simon two-stage design (H0 = 40%, H1 = 60%, α = 0.05, β = 0.2) by Response Evaluation Criteria In Solid Tumors 1.0 was applied.<bold>Results: </bold>Fifty-one patients were enrolled. Confirmed response was recorded in 46 patients. One patient achieved complete response and 33 patients achieved partial response (response rate 34/51 [66.7%] in the intent-to-treat population). Median follow-up time was 28.6 months, with a median progression-free survival of 9.2 months (95% confidence interval [CI]: 6.5-11.6) and a median overall survival (OS) of 19.5 months (95% CI: 15.5-26.0). Patients with a HER2/CEP17 ratio of greater than five achieved improved OS (20.9 vs 19.5 months, p = 0.001). The most common adverse events of grade 3 or above were thrombocytopenia (21.6%), neutropenia (13.7%), anemia (5.9 %) and leucopenia (3.9%).<bold>Conclusion: </bold>The addition of trastuzumab to oxaliplatin/capecitabine was well tolerated and the results demonstrated encouraging efficacy.<bold>Trial Registration: </bold>ClinicalTrials.gov NCT01364493.
- Subjects
TRASTUZUMAB; OXALIPLATIN; COMBINATION drug therapy; STOMACH cancer treatment; CANCER chemotherapy; DRUG efficacy; CLINICAL trials; EPIDERMAL growth factor receptors; ANTINEOPLASTIC agents; CELL receptors; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; ORGANOPLATINUM compounds; PROGNOSIS; RESEARCH; STOMACH tumors; TUMOR classification; EVALUATION research
- Publication
BMC Cancer, 2016, Vol 16, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-016-2092-9